Navigation Links
Thoratec Reports 44 Percent Increase in Third Quarter Revenues
Date:10/30/2008

Company Increases Revenue and Earnings Guidance for 2008 Based on

Continuing Adoption of HeartMate II(R)

PLEASANTON, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today said that revenues for the third quarter of 2008 increased 44 percent over revenues in the same period a year ago.

Revenues for the quarter ended September 27, 2008, were $80.8 million versus $56.1 million in the third quarter of 2007. Net income on a GAAP basis in the third quarter of 2008 was $7.2 million, or $0.12 per diluted share, compared with a net loss on a GAAP basis of $1.4 million, or $0.03 per share, in the same period a year ago. Non-GAAP net income, which is described later in this press release, was $10.5 million, or $0.17 per diluted share, compared with non-GAAP net income of $2.5 million, or $0.04 per diluted share, in the third quarter of 2007.

For the first nine months of fiscal 2008, revenues were $227.9 million, a 34 percent increase over revenues of $170.7 million in the first nine months of fiscal 2007. On a GAAP basis, Thoratec reported net income of $16.2 million, or $0.28 per diluted share, versus a net loss of $430,000, or $0.01 per share, in the same period a year ago. Non-GAAP net income for the first nine months of fiscal 2008 was $27.1 million, or $0.45 per diluted share, compared with non-GAAP net income of $12.0 million, or $0.22 per diluted share, in the first nine months of fiscal 2007.

"As was the case last quarter, our strong financial performance was driven by the continued adoption of the HeartMate II LVAS (Left Ventricular Assist System
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
2. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
3. Thoratec Presentation at JP Morgan Conference to be Webcast
4. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
5. Thoratec Presentation at Bear Stearns Conference To Be Webcast
6. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
7. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
10. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
11. United Therapeutics Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... 2014  CorMedix Inc. (NYSE MKT: CRMD), a ... products for the prevention and treatment of cardiorenal ... on July 18, 2014 from the NYSE MKT ... CorMedix plan to regain compliance with continued listing ... NYSE-MKT is continuing the Company,s listing and has ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... WAYNE, Pa., May 15 Escalon Medical Corp.,(Nasdaq: ... quarter and,nine months ended March 31, 2008., For ... 18% to,$8,139,000 compared with $6,900,000 reported in the same ... sales in each of the,Company,s business units., Net ...
... biotechnology company that is focused on the development of,autologous (patient-derived) ... heart damage, today announced financial results for,the quarter ended March ... 19, 2008, the Company completed its initial public offering ... of approximately $5.8 million. The net ...
... Advisory Panel reacts to CMS final rule; ... identifies challenges, recommends strategies, ... Inc. and,the International Expert Wound Care Advisory Panel ... Improve Pressure,Ulcer Prevention and Treatment: Implications of the ...
Cached Biology Technology:Escalon(R) Reports Third Quarter Fiscal 2008 Results 2Escalon(R) Reports Third Quarter Fiscal 2008 Results 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 4Escalon(R) Reports Third Quarter Fiscal 2008 Results 5Escalon(R) Reports Third Quarter Fiscal 2008 Results 6Escalon(R) Reports Third Quarter Fiscal 2008 Results 7Escalon(R) Reports Third Quarter Fiscal 2008 Results 8Bioheart, Inc. Announces Financial Results for First Quarter 2008 2Bioheart, Inc. Announces Financial Results for First Quarter 2008 3Bioheart, Inc. Announces Financial Results for First Quarter 2008 4Bioheart, Inc. Announces Financial Results for First Quarter 2008 5Bioheart, Inc. Announces Financial Results for First Quarter 2008 6Bioheart, Inc. Announces Financial Results for First Quarter 2008 7International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 3
(Date:7/24/2014)... NY (July 24, 2014) Scientists at The ... are one step closer to creating a viable ... patient,s own cells. , For the first ... cells lines from skin samples of patients with ... an accelerated protocol to induce these stem cells ...
(Date:7/24/2014)... Citing many sobering examples of how wildlife loss leads ... article co-authored by Wildlife Conservation Society (WCS) Health ... Christopher Golden, calls for an interdisciplinary approach to tackle ... directly supports about 15% of the world,s people and ... world,s poor. It should come as no surprise that ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... acne (Propionibacterium acnes) will be the topic of the Denver ... University. As well as acne, this bacterium is responsible for ... diagnosis. Why are we not more aware of this versatile ... and boost the immune system: , Probiotics can ...
... Most college students in the United States do ... an essential skill in understanding the causes and ... the January issue of BioScience . The ... from Michigan State University, calls for a new way ...
... Scientists at Rothamsted Research, United Kingdom, in collaboration with ... Areas (ICARDA), Syria have developed a method of accounting ... trend refers to the variations in crop yield and ... trial. Usually plant breeders will grow several replicate ...
Cached Biology News:Probiotics, prebiotics and biofuel-producing bacteria 2College students lack scientific literacy, study finds 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
... Protein size: 325 Accession ... using peptide based assay: 1:1562500 ... 1.0g/ml in 5% skim milk / ... should be diluted in 1: 50,000 - ...
... 4503277 Accession Number: NP_001912.1 ... the nucleotide substrate for thymidylate synthetase. ... O = dUMP + NH 3 ... the Diseases: Benign Tumor; Leukemia; Escherichia ...
Active GST Protein...
Biology Products: